NA Proactive news snapshot: Karora Resources, American Manganese, Idaho Champion Gold Mines Canada, MedX Health, Lingo Media UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Company
Willow Biosciences Inc
TSE:WLLW
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow’s FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow’s R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com .
85 stories · page 4 of 5
Willow Biosciences strikes first commercial supply agreement for CBG with UK cosmetics firm Cellular Goods
Cellular Goods will use Willow’s ultra-pure cannabigerol in its premium cannabinoid-based skincare products that are to be launched later in the year
Willow Biosciences added to NYSE-listed Cannabis ETF
It has been added to The Cannabis ETF, which contains 33 stocks that are expected to benefit from the growth of the legal global marijuana, cannabidiol and hemp industries
Willow Biosciences CEO Trevor Peters discusses how biosynthetically produced cannabinoids could shake up the cannabis industry
Willow's biosynthetic approach to creating THC, CBG and other plant-derived ingredients takes farming and plant-processing out of the picture, bringing benefits on environmental, cost and inventory management fronts
WIllow Biosciences ends 1Q with C$46.5M as it looks to its first CBG sales in 2Q
The Canadian biotechnology company further optimized its proprietary yeast strain to produce THC and completed its first commercial-scale fermentation run of CBG
Willow Biosciences reveals new clinical data showing the effectiveness of CBG on human skin
The company said studies have shown that Willow’s CBG is safe when applied to skin and eye areas, paving the way for its use in skincare
Willow Biosciences completes first commercial-scale fermentation run of ultra-pure CBG
Willow has already executed successful pilot production runs to optimize its process and provide samples of CBG to customers
Archive
NA Proactive news snapshot: WeedMD, Endeavour Mining, Newrange Gold, American Battery Metals, Power REIT UPDATE …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Willow Biosciences on track to commercialize ultra-pure cannabinoids in 2021 with over C$47M in the bank
The company ended its 4Q 2020 with nearly C$16 million in cash on hand, a number that increased after a bought deal and warrant exercise in 1Q 2021
Willow Biosciences closes upsized bought deal offering for aggregate gross proceeds of approximately $28.75M after full exercise of over-allotment option
The company noted that participation in the Offering was comprised primarily of existing cornerstone shareholders and new institutional buyside funds
Willow Biosciences upsizes bought-deal financing raise to $25 million from initial $20.0 million
The net proceeds are expected to be used to help access new markets for its cannabinoid portfolio, expedite the commercialization of new cannabinoids, access additional manufacturing capacity, and working capital
Willow Biosciences is set to benefit from Jazz Pharmaceuticals acquisition of GW Pharmaceuticals
Willow Biosciences CEO Trevor Peters told Proactive the acquisition validates cannabinoids as having true pharmacological potential beyond treating childhood epilepsy
Willow Biosciences says it will be the first company to launch biosynthetically-produced THC in Canada
The Canadian company plans to commercialize the proprietary THC-producing yeast strain after it successfully launches its CBG-producing strain early this year
Willow Biosciences undertaking initiatives to help its customers evaluate and better understand CBG
CBG, or cannabigerol, is its first commercial cannabinoid that is slated for production in 1Q 2021
Willow Biosciences moves towards revenue generation as it expects first sales of CBG in second quarter of 2021
The biotech told investors it had selected a contract manufacturing organization to manufacture its first cannabinoid, cannabigerol (CBG)
Willow Biosciences ends 3Q with C$9.1M in cash after successful pilot production of CBG
CEO Trevor Peters said the quarter represented a “significant move forward” for the Calgary-based company ahead of commercial production anticipated to begin in 2021
Willow Biosciences CEO Trevor Peters is confident that the company will be the first to produce cannabigerol
The CEO shares exclusively with Proactive how the company plans to cross the finish line with commercial quantities of CBG
Willow Biosciences closes C$11.5M offering for cannabinoid commercialization
The company offered roughly 17.7 million units, each containing one share and one half a purchase warrant, at a price of C$0.65 per unit
Willow Biosciences boosts offering to $10 million due to excess demand
Willow has developed a proprietary process to produce high purity, plant-derived CBG and CBD compounds for the global pharmaceutical, health and wellness, and consumer packaged goods industries
Willow Biosciences partners with Lethbridge and Calgary universities to study the effects of non-psychoactive cannabinoids on intestinal inflammation, abdominal pain and depression
To support the research, Willow will be providing four different, non-plant derived cannabinoids for use in the study, which is set to begin in the 4Q of 2020